HCV Related Hepatocellular Carcinoma Recurrence After Directly Acting Antivirals: A Randomized Controlled Trial
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
Data regarding hepatocellular carcinoma (HCC) recurrence after directly acting antivirals
(DAAs) given for hepatitis C virus treatment are contradictory. Surprisingly, some studies
reported that DAAs are accompanied with higher HCC recurrence. But, other studies showed no
rise or even decrease in HCC recurrence. Most of these studies were retrospective and some
were non-randomized prospective studies. Here investigators aim to perform a randomized
controlled trial to study this issue.